ダウンロード数 : ?
ファイル
言語
英語
著者
KOHNO, Kunie Research Center for prevention of lifestyle-related disease
HONDA, Sakae Honda Dermatological Clinic
TOHGI, Kimiko Togi Dermatological Clinic
新原 寛之 医学部
千貫 祐子 医学部
MIHARA, Yuko Shimane Prefectural Central Hospital
太田 征孝 医学部
塩飽 邦憲
内容記述(抄録等)
Pruritus is a condition in which itch occurs in the absence of apparent skin lesions. It is sometimes unresponsive to treatment with topical moisturizers and often is unresponsive to antihistamines. We evaluated the antipruritic effects of Neurotropin injections in patients with moisturizer- and antihistamine-resistant pruritus. We monitored these patients by itch scores recorded in symptom diaries, as well as reports of quality of life (QOL). This study investigated both the efficacy and safety of Neurotropin injections using an open-label study design. We enrolled 40 patients from six participating study sites. Of the 40 patients that were initially enrolled, 6 patients were ineligible, and ultimately, 33 were included for evaluation after one patient dropped out. Neurotropin 1was administered by subcutaneous injection to 22 patients and intravenous injection to 11 patients at a frequency of once per week. Compared to data collected during a 1-week observation period prior to treatment, after 7 injections of Neurotropin, there was a significant improvement in the Shiratori symptom severity score and the visual analog scale (VAS) scores for itch symptoms, and the Dermatology Life Quality Index (DLQI) for quality of life. No new adverse events occurred during the period of investigation. A notable benefit to Neurotropin is that it can be used in patients with renal impairment and patients receiving dialysis therapy. Our results demonstrated that Neurotropin is effective in the treatment of moisturizer- and antihistamine-resistant pruritus.
主題
pruritus
Neurotropin
itch
Shiratori severity score
DLQI
掲載誌名
Journal of Cutaneous Immunology and Allergy
1
3
開始ページ
109
終了ページ
116
ISSN
2574-4593
発行日
2018
DOI
資料タイプ
学術雑誌論文
ファイル形式
PDF
著者版/出版社版
著者版
部局
医学部